Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has provided an update.
Alligator Bioscience AB has released its annual report for 2025, outlining a year centered on advancing its portfolio of tumor-targeted immunotherapies for cancer treatment. The report details significant events, financial performance and strategic initiatives aimed at strengthening the company’s position in the oncology biotech market.
The document highlights progress across key programs including mitazalimab, ATOR-4066 and ALG.APV-527, as well as the company’s collaborations and licensing activities. It also provides an overview of market conditions, risks, sustainability efforts and corporate governance, offering stakeholders a comprehensive view of Alligator’s operational and strategic development during 2025.
The most recent analyst rating on (SE:ATORX) stock is a Sell with a SEK0.16 price target. To see the full list of analyst forecasts on Alligator Bioscience AB stock, see the SE:ATORX Stock Forecast page.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company focused on pioneering immunotherapies for tumor-targeted cancer treatment. The company develops antibody-based drug candidates such as mitazalimab, ATOR-4066 and ALG.APV-527, and advances them through clinical and preclinical development, collaborations and licensing agreements to address unmet needs in oncology.
YTD Price Performance: -47.92%
Average Trading Volume: 5,292,024
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK93.86M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.